AR064370A1 - NITRO-DERIVATIVES OF BENCENOSULFONAMIDS REPLACED AS CARBON ANHYDRATION INHIBITORS PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PHARMACEUTICAL KITS FOR THEIR ADMINISTRATION AND USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND OCULAR - Google Patents

NITRO-DERIVATIVES OF BENCENOSULFONAMIDS REPLACED AS CARBON ANHYDRATION INHIBITORS PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PHARMACEUTICAL KITS FOR THEIR ADMINISTRATION AND USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND OCULAR

Info

Publication number
AR064370A1
AR064370A1 ARP070105642A ARP070105642A AR064370A1 AR 064370 A1 AR064370 A1 AR 064370A1 AR P070105642 A ARP070105642 A AR P070105642A AR P070105642 A ARP070105642 A AR P070105642A AR 064370 A1 AR064370 A1 AR 064370A1
Authority
AR
Argentina
Prior art keywords
group
ono2
alkyl
formula
cancer
Prior art date
Application number
ARP070105642A
Other languages
Spanish (es)
Inventor
Stefano Biondi
Claudiu Supuran
Francesca Benedini
Ennio Ongini
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of AR064370A1 publication Critical patent/AR064370A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/53—X and Y not being nitrogen atoms, e.g. N-sulfonylcarbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/26—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Abstract

Se describen los nitroderivados que se pueden emplear para el tratamiento de glaucoma, hipertension ocular, degeneracion macular relacionada con la edad, edema macular diabética, retinopatía diabética, retinopatía hipertensiva y vasculopatías retinianas, cáncer, epilepsia, trastorno de altura y enfermedades neuromusculares. Reivindicacion 1: Uso de un inhibidor de anhidrasa carbonica capaz de liberar oxido nítrico para la preparacion de un medicamento para el tratamiento de trastornos oculares y cáncer. Reivindicacion 5: Un compuesto de formula general (1) o una de sus sales aceptables para uso farmacéutico o estereoisomeros: R-(X-Y-ONO2)s, caracterizado porque s es un numero entero igual a 1 o 2; R se selecciona del grupo que consiste en formulas (2a) a (2g), donde n es un numero de 0 a 4; m es un numero entero igual a 0 o 1; R1, R2 y R3 son iguales o diferentes y son H, CI, Br, I, F, CF3, SO2NH2; X1 es -O- o -NH-; N1 es -OH, -COOH, -O-, -C(O)-, -NHR1 o -NR1- donde R1 es H o alquilo C1-6; R' es H o un grupo -(X-Y-ONO2); X es -C(O)-, -O-, -NR1-, -S-, -C(O)O- o -C(O)S-, donde R1 es H o alquilo C1-6; con la condicion de que i) cuando el grupo -(X-Y-ONO2) está unido a N1 entonces: - N1 es -O- o -NR1- y X es -C(O)-, - C(O)O- o -C(O)S-, donde R1 es H o alquilo C1-6; -N1, es -C(O)- y X es -O-, -NR1-, -S-, -C(O)O- o -C(O)S-, donde R1 es H o alquilo C1-6; ii) cuando R' es -(X-Y-ONO2) entonces X es -C(O)-, -C(O)O- o -C(O)S-; iii) cuando s es 2, entonces -X y -Y- de lo dos grupos -(X-Y-ONO2) pueden ser iguales o diferentes; Y es un radical bivalente que tiene el siguiente significado: a) alquileno C1-20 lineal o ramificado; alquileno C1-20 lineal o ramificado sustituido con uno o más de los sustituyentes seleccionados del grupo que consiste en átomos de halogeno, hidroxi, -ONO2 o T, donde T es -OC(O)(alquilo C1-10)-ONO2 u -O(alquilo C1-10)-ONO2; cicloalquileno con 5 a 7 átomos de carbono del anillo cicloalquileno, el anillo está opcionalmente sustituido con cadenas laterales T1, donde T1 es un alquilo C1-10 lineal o ramificado; b) grupo de formula (3); c) grupo de formula (4) donde n0 es un numero de 0 a 20, n1 es un numero de 1 a 20, d) un grupo de formula (5) donde X1 = -OC(O)- o - C(O)O-; n2 es un numero de 0 a 2; R2 es H o CH3; Z es -(CH2)n1- o el radical bivalente definido anteriormente con b), donde n1 es un numero de 1 a 20; e) es un grupo con las formulas (6) y (7) donde Y1 es -CH2-CH2-(CH2)n2a- o -CH=CH-(CH2)n2a- donde n2a es de 0 a 2, X1 es -OC(O)- o -C(O)O-, n2 es un numero de 0 a 2, R2 es H o CH3, Z es -(CH2)n1- o el radical bivalente definido anteriormente en b), donde n1 es un numero de 1 a 20; cuando Y se selecciona de los radicales bivalentes mencionados en b) -e), entonces el grupo terminal -ONO2 está unido a -(CH2)n1; f) grupos (8) y (9) donde: n1'es un numero de 1 a 20, R3 es H, R0 es H o -COCH3; con la condicion de que cuando Y se selecciono entre los radicales bivalentes mencionados en f), entonces el grupo -ONO2 está unido a -(CH2)n1; g) -(CH2-X2)-CH2-CH2- , (g') -(R2)(CH-CH2-X2)n3-CH(R2)CH2- (gö) el grupo de formula (10) donde X2 es -O- o -S-, n3 es un numero de 1 a 6, R2 es H o -CH3 h) un grupo de formula (11) donde: n4 es un numero de 0 a 10; n5 es un numero de 1 a 10; R4, R5, R6, R7 son iguales o diferentes, y son H o alquilo C1-4 lineal o ramificado; donde el grupo -ONO2 está unido a -[C]n5 donde n5 es como se definio anteriormente; Y2 es un anillo heterocíclico saturado, insaturado o aromático de 5 o 6 miembros, que contiene uno o más heteroátomos seleccionados entre nitrogeno, oxígeno, azufre, y se selecciona entre los grupos de formulas (Y1) a (Y13)Nitroderivatives that can be used for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies, cancer, epilepsy, height disorder and neuromuscular diseases are described. Claim 1: Use of a carbonic anhydrase inhibitor capable of releasing nitric oxide for the preparation of a medicament for the treatment of eye disorders and cancer. Claim 5: A compound of general formula (1) or one of its salts acceptable for pharmaceutical or stereoisomeric use: R- (X-Y-ONO2) s, characterized in that s is an integer equal to 1 or 2; R is selected from the group consisting of formulas (2a) to (2g), where n is a number from 0 to 4; m is an integer equal to 0 or 1; R1, R2 and R3 are the same or different and are H, CI, Br, I, F, CF3, SO2NH2; X1 is -O- or -NH-; N1 is -OH, -COOH, -O-, -C (O) -, -NHR1 or -NR1- where R1 is H or C1-6 alkyl; R 'is H or a group - (X-Y-ONO2); X is -C (O) -, -O-, -NR1-, -S-, -C (O) O- or -C (O) S-, where R1 is H or C1-6 alkyl; with the proviso that i) when the group - (XY-ONO2) is linked to N1 then: - N1 is -O- or -NR1- and X is -C (O) -, - C (O) O- or -C (O) S-, where R1 is H or C1-6 alkyl; -N1, is -C (O) - and X is -O-, -NR1-, -S-, -C (O) O- or -C (O) S-, where R1 is H or C1-6 alkyl ; ii) when R 'is - (X-Y-ONO2) then X is -C (O) -, -C (O) O- or -C (O) S-; iii) when s is 2, then -X and -Y- of the two groups - (X-Y-ONO2) can be the same or different; And it is a bivalent radical that has the following meaning: a) linear or branched C1-20 alkylene; linear or branched C1-20 alkylene substituted with one or more of the substituents selected from the group consisting of halogen, hydroxy, -ONO2 or T atoms, where T is -OC (O) (C1-10 alkyl) -ONO2 or - O (C1-10 alkyl) -ONO2; cycloalkylene with 5 to 7 carbon atoms of the cycloalkylene ring, the ring is optionally substituted with T1 side chains, where T1 is a linear or branched C1-10 alkyl; b) group of formula (3); c) formula group (4) where n0 is a number from 0 to 20, n1 is a number from 1 to 20, d) a group of formula (5) where X1 = -OC (O) - or - C (O )OR-; n2 is a number from 0 to 2; R2 is H or CH3; Z is - (CH2) n1- or the bivalent radical defined above with b), where n1 is a number from 1 to 20; e) is a group with formulas (6) and (7) where Y1 is -CH2-CH2- (CH2) n2a- or -CH = CH- (CH2) n2a- where n2a is 0 to 2, X1 is - OC (O) - or -C (O) O-, n2 is a number from 0 to 2, R2 is H or CH3, Z is - (CH2) n1- or the bivalent radical defined above in b), where n1 is a number from 1 to 20; when Y is selected from the bivalent radicals mentioned in b) -e), then the -ONO2 terminal group is attached to - (CH2) n1; f) groups (8) and (9) where: n1'is a number from 1 to 20, R3 is H, R0 is H or -COCH3; with the proviso that when Y was selected from the bivalent radicals mentioned in f), then the group -ONO2 is linked to - (CH2) n1; g) - (CH2-X2) -CH2-CH2-, (g ') - (R2) (CH-CH2-X2) n3-CH (R2) CH2- (gö) the group of formula (10) where X2 is -O- or -S-, n3 is a number from 1 to 6, R2 is H or -CH3 h) a group of formula (11) where: n4 is a number from 0 to 10; n5 is a number from 1 to 10; R4, R5, R6, R7 are the same or different, and are H or C1-4 linear or branched alkyl; where the group -ONO2 is linked to - [C] n5 where n5 is as defined above; Y2 is a saturated, unsaturated or aromatic 5 or 6 membered heterocyclic ring, which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from the groups of formulas (Y1) to (Y13)

ARP070105642A 2006-12-15 2007-12-14 NITRO-DERIVATIVES OF BENCENOSULFONAMIDS REPLACED AS CARBON ANHYDRATION INHIBITORS PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PHARMACEUTICAL KITS FOR THEIR ADMINISTRATION AND USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND OCULAR AR064370A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87494206P 2006-12-15 2006-12-15

Publications (1)

Publication Number Publication Date
AR064370A1 true AR064370A1 (en) 2009-04-01

Family

ID=39183167

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105642A AR064370A1 (en) 2006-12-15 2007-12-14 NITRO-DERIVATIVES OF BENCENOSULFONAMIDS REPLACED AS CARBON ANHYDRATION INHIBITORS PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PHARMACEUTICAL KITS FOR THEIR ADMINISTRATION AND USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND OCULAR

Country Status (2)

Country Link
AR (1) AR064370A1 (en)
WO (1) WO2008071421A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK542007A3 (en) * 2007-04-20 2008-11-06 Unimed Pharma, Spol. S R. O. Substituted sulfonamides, process for preparing them, medicament containing them and their use
US9085508B2 (en) 2008-09-24 2015-07-21 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester compound, composition and method of use
JP2012503606A (en) * 2008-09-24 2012-02-09 ニトロジェニックス インコーポレイティッド Nitric oxide releasing amino acid ester compounds, compositions and methods of use
US8062653B2 (en) 2009-02-18 2011-11-22 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
EP2533775A1 (en) * 2010-02-12 2012-12-19 Universita' Degli Studi di Firenze Carbonic anhydrase inhibitors
NL1038473C2 (en) * 2010-12-24 2012-06-27 Centre Nat Rech Scient Cancer targeting using carbonic anhydrase isoform ix inhibitors.
WO2012175654A1 (en) 2011-06-23 2012-12-27 Facultes Universitaires Notre-Dame De La Paix Tetraline sulfonamide derivatives for use in the treatment of proliferative disorders
CN102675404B (en) * 2012-05-10 2014-04-09 福建天泉药业股份有限公司 Preparation method of glycyrrhetinic acid butyl nitrate
ITRM20130138A1 (en) 2013-03-07 2014-09-08 Consiglio Nazionale Ricerche ASSEMBLED INCLUDING A LIGHT ABSORBER IN THE INFRARED NEIGHBOR ENTITLELY TIED TO AN INHIBITOR OF THE CARBON DIVE
WO2015025283A2 (en) 2013-08-20 2015-02-26 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Dual action carbonic anhydrase inhibitors
CN104478727A (en) * 2014-12-22 2015-04-01 江西本草天工科技有限责任公司 Ferulic acid derivatives capable of releasing nitrogen monoxide and application thereof
LT6401B (en) 2015-07-28 2017-06-12 Vilniaus Universitetas Selective inhibitors of carbonic anhydrase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087630B2 (en) * 2002-06-27 2006-08-08 Nitromed, Inc. Cyclooxygenase 2 selective inhibitors, compositions and methods of use
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
EP1704141B1 (en) * 2004-01-05 2016-02-24 Nicox S.A. Prostaglandin nitrooxyderivatives
US20080300292A1 (en) * 2004-11-08 2008-12-04 Nitromed, Inc Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders
CA2597460A1 (en) * 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use

Also Published As

Publication number Publication date
WO2008071421A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
AR064370A1 (en) NITRO-DERIVATIVES OF BENCENOSULFONAMIDS REPLACED AS CARBON ANHYDRATION INHIBITORS PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PHARMACEUTICAL KITS FOR THEIR ADMINISTRATION AND USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND OCULAR
AR064420A1 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AN EFFECTIVE AMOUNT OF ANALOGS OF 6-AMINOIMIDAZO [1,2B] PIRIDAZINAS, USEFUL FOR THE TREATMENT OF GLAUCOMA AND / OR CONTROL THE NORMAL OR ELEVATED INTRAOCULAR PRESSURE (IOP).
AR056838A1 (en) 1,2,5-TIADIAZOL DERIVATIVES
EP2597953A4 (en) Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
AR061238A1 (en) HEPATITIS C PROTEASE INHIBITORS MACROCICLIC OXYLMYL COMPOUNDS
DOP2010000143A (en) COMPOUNDS CONTAINING QUINOXALINE AS INHIBITORS OF THE HEPATITIS C VIRUS
DOP2013000062A (en) INHIBITORS OF HCV SERINE PROTEASES DERIVED FROM MACROCYCLINE PROLINES
AR055606A1 (en) BENZOQUINAZOLINE DERIVATIVES
TW200621772A (en) Compounds which increase apolipoprotein a-1 production and uses thereof in medicine
EA200900582A1 (en) PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF EYE PATHOLOGIES
AR078201A1 (en) COMPOUNDS OF 2-PIRIDONA AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY THE ELASTASA OF NEUTROFILOS
CY1117792T1 (en) COMPETITORS TOY TRPV4
UY28695A1 (en) DERIVATIVES OF DIFENILAZETIDONA
EA200700901A1 (en) DERIVATIVES 2-AMIDO-4-PHENYL THIAZOLE, THEIR OBTAINING AND USE IN THERAPY
AR072666A1 (en) DERIVATIVES OF NIP TIAZOL AS INHIBITORS OF THE 11-BETA-HYDROXIESTEROID DEHYDROGENASE-1 (11-B-HSD-1)
PE20110384A1 (en) DERIVATIVES OF ALKYLTIAZOLES CARBAMATES AND THEIR PREPARATION
AR061598A1 (en) HETEROCICLIC NITRO-DERIVATIVES AS ENDOTHELINE RECEIVER ANTAGONISTS
AR061583A1 (en) ACIDS 6- (BENCILO REPLACED WITH HETEROCICLIL) -4-CARBOXYL OXYQUINOLIN, HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS ANTI-HIV AGENTS.
RU2007137115A (en) NEW OPHTHALMIC COMPOSITIONS AND WAYS OF THEIR APPLICATION
BRPI0414699A (en) anecortave acetate and triamcinolone acetonide formulations for injection
ECSP22038478A (en) HETEROARYL BIPHENYL AMIDES FOR THE TREATMENT OF DISEASES RELATED TO THE PD-L1 LIGAND
CO2022004698A2 (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
UY27685A1 (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS, AND PROCEDURES FOR USE
ECSP088257A (en) AMIDA DERIVATIVES
AR057570A1 (en) DERIVATIVES OF N-SULFAMOIL-N'-BENZOPIRANOPIPERIDINAS ESPIROCONDENSADAS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A PROCEDURE FOR THEIR PREPARATION AND ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY ISOIDAS IIB

Legal Events

Date Code Title Description
FB Suspension of granting procedure